Market Data 
Markets
Replies to post #319712 on Innovation Pharmaceuticals Inc (IPIX)
08/22/20 12:03 PM
08/22/20 12:27 PM
08/22/20 1:19 PM
The way I visualize Brilacidin's MOAs:
Once the drug enters the circulation it can destroy the virus on contact by attaching to and penetrating the viral coating or capsid.This opens a pore in the coating and results in the destruction of the virus. This virucidal MOA rapidly destroys the virus. This may be the most important MOA and Briliacidn seems to be the only Coronvirus antiviral being studied with this unique MOA.
Any virus that escapes is blocked from entering cells by Brilacidin's ability to bind the viral S or spike protein from attaching to the cell wall ACE protein which seems to be Coronavirus's only point of entry.
When cells are infected the virus hijacks the cells intracellular processes to manufacture more virus. Brilacidin has the ability to enter the infected cells and attach to and deactivate the viral main protease which is one of the key viral components to begin viral replication. Most antivirals, eg Remdesivir, work by only blocking viral reproduction as nucleic base analogues which are incorporated into the viral RNA [ or DNA in DNA viruses] and prevent RNA replication for the new viruses.
Brilacidin's theoretic advantages over other treatments are it quickly reduces the viral "load" which should reduce the severity of illness and the systemic complications. Its triple mechanism of action will make viral resistance much more difficult and make Brilacidin more active against mutated viruses which seem to be emerging.By destroying the virus at an early stage it will release viral antigens into the circulation which which will recruit the immune system to attack the virus. The immunomodulating abilities may prevent the immune system from over reacting and causing the Cytokine storm and ARDS which has resulted in the severe lung complications. Pulmonary failure is the most common cause of death in Covid19.Its broad spectrum antibiotic abilities will reduce secondary bacterial complications in the severely ill patients
The RBL and past ABSSSI studies suggest Brilacidin could be a superior antiviral which may have many advantages over current treatments in terms of reducing mortality and complications.It appears to be a much safer drug.
An effective anti viral will be an essential part of any treatment plan for Covid19. Remdesivir has not been able to show it can reduce mortality or complications so the bar for Brilacidin's success is very low.
Hopefully Brilacidin can break the strangle hold the pandemic has on the health, economy and psyche of the country and world.
The next few weeks should be exciting times for IPIX long term investors.
Good luck,Farrell
The way I visualize Brilacidin's MOAs:
Once the drug enters the circulation it can destroy the virus on contact by attaching to and penetrating the viral coating or capsid.This opens a pore in the coating and results in the destruction of the virus. This virucidal MOA rapidly destroys the virus. This may be the most important MOA and Briliacidn seems to be the only Coronvirus antiviral being studied with this unique MOA.
Any virus that escapes is blocked from entering cells by Brilacidin's ability to bind the viral S or spike protein from attaching to the cell wall ACE protein which seems to be Coronavirus's only point of entry.
When cells are infected the virus hijacks the cells intracellular processes to manufacture more virus. Brilacidin has the ability to enter the infected cells and attach to and deactivate the viral main protease which is one of the key viral components to begin viral replication. Most antivirals, eg Remdesivir, work by only blocking viral reproduction as nucleic base analogues which are incorporated into the viral RNA [ or DNA in DNA viruses] and prevent RNA replication for the new viruses.
Brilacidin's theoretic advantages over other treatments are it quickly reduces the viral "load" which should reduce the severity of illness and the systemic complications. Its triple mechanism of action will make viral resistance much more difficult and make Brilacidin more active against mutated viruses which seem to be emerging.By destroying the virus at an early stage it will release viral antigens into the circulation which which will recruit the immune system to attack the virus. The immunomodulating abilities may prevent the immune system from over reacting and causing the Cytokine storm and ARDS which has resulted in the severe lung complications. Pulmonary failure is the most common cause of death in Covid19.Its broad spectrum antibiotic abilities will reduce secondary bacterial complications in the severely ill patients
The RBL and past ABSSSI studies suggest Brilacidin could be a superior antiviral which may have many advantages over current treatments in terms of reducing mortality and complications.It appears to be a much safer drug.
An effective anti viral will be an essential part of any treatment plan for Covid19. Remdesivir has not been able to show it can reduce mortality or complications so the bar for Brilacidin's success is very low.
Hopefully Brilacidin can break the strangle hold the pandemic has on the health, economy and psyche of the country and world.
The next few weeks should be exciting times for IPIX long term investors.
Good luck,Farrell
AI
